Sihuan Pharmaceutical (HKG:0460) said the new drug application of the Bireociclib tablets, developed by unit Xuanzhu Biopharmaceutical, has been approved by China's National Medical Products Administration for two indications, a Thursday Hong Kong bourse filing said.
The first indication is as monotherapy for adult patients with local advanced or metastatic breast cancer, while the second involves the drug in combination with Fulvestrant for the treatment of adult patients with HER2-advanced or metastatic breast cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.